Discussion about this post

User's avatar
PitchStack Investing's avatar

Hey mate!

Given your interest in Biotech, you might enjoy my recent piece on eXoZymes Inc. They’ve just commercially launched a cell-free enzyme biocatalysis platform that converts biofeedstocks into targeted chemical products.

Plus they just announced their first subsidary which synthesises N-trans-caffeoyltyramine (NCT) to treat MASLD/MASH. Very very interesting compound that has immense potential

https://www.slack-capital.com/p/exozymes-research-report

Expand full comment